Klaus Podar

11PUBLICATIONS
24CO-AUTHORS
Molecular targetsHaematological tumoursGene and molecular therapyPredictive and prognostic markersMedical infection agents (incl. prions)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (11)

|Aug 19, 2024
Dual therapeutic targeting of MYC and JUNB transcriptional programs for enhanced anti-myeloma activity.

Judith Lind, Osman Aksoy, Michaela Prchal-Murphy

|Jan 21, 2023
Evaluation of Antibody Responses in Patients with B-Cell Malignancies after Two and Three Doses of Anti-SARS-CoV-2 S Vaccination-A Retrospective Cohort Study.

Stella Rosa Maria Wirth, Klaus Podar, Martin Pecherstorfer

|Oct 23, 2021
Relapsed/Refractory Multiple Myeloma in 2020/2021 and Beyond.

Klaus Podar, Xavier Leleu

|Sep 10, 2021
Evaluation of Antibody Responses to COVID-19 Vaccines among Solid Tumor and Hematologic Patients.

Josef Singer, Nguyen-Son Le, Daniel Mattes

|Jun 02, 2021
The Role of AP-1 Transcription Factors in Plasma Cell Biology and Multiple Myeloma Pathophysiology.

Fengjuan Fan, Klaus Podar

|May 19, 2021
JunB is a key regulator of multiple myeloma bone marrow angiogenesis.

Fengjuan Fan, Stefano Malvestiti, Sonia Vallet

Pageof 2

Frequent Collaborators

4 joint publications

Fengjuan Fan

3 joint publications

Andreas Stadlbauer

3 joint publications

Latifa Bakiri

2 joint publications

Yu Hu